Australia is experience potentially transformative treatment for weight issues: Retatrutide. This new dual agonist – working on both GLP-1 and GIP receptors – demonstrates promising efficacy in clinical studies, pointing to substantial reductions in BMI. While regulatory clearance hasn't occurred